This time last year, global spending on biomedical research was holding up reasonably well (Macilwain, 2011) , especially considering the forlorn state of the world's economy. But as 2012 dawns, the full impact of the great recession is about to be felt in the laboratory, according to an informal Cell survey of research spending trends in 15 leading nations.
It is tricky to compare biomedical research spending across nations. Annual budgets are at different stages of development, and the best published data, which is collated by the Paris-based Organization for Economic Cooperation and Development (OECD), is usually 2-3 years out of date. Although inflation should also be taken into account, salaries account for the bulk of research costs, and given that they are now frozen for publicly employed researchers in most Western nations, agencies do not need inflation-linked increases to maintain levels of activity. Accordingly, the anticipated changes in spending noted here do not allow for national inflation rates.
Nonetheless, by trawling through published documents and interviewing researchers, officials, and analysts in 15 nations, it is possible to estimate how global funding for biomedical research is evolving at the beginning of 2012.
Stimulus Shrinks in the US
A cold wind was set in motion when Lehman Brothers went bust in October 2008, leading to an economic slowdown across Western nations. Now in 2012, this economic cooling will hit laboratories, and it will be felt most fully by life scientists in the United States, which spends more on biomedical research than the rest of the world combined, according to most assessments.
The $30 billion budget of the National Institutes of Health (NIH) has basically remained flat over the past 3 years, but it has maintained its spending power through a temporary $10 billion supplement for NIH in the stimulus bill signed by President Barack Obama in February 2009.
Money from that package, which peaked in 2010 and 2011, will now rapidly fade away. ''You're going to go from $3 billion in stimulus funds to a few hundred million, between 2011 and 2013,'' says Howard Garrison, head of policy at the Federation of American Scientists for Experimental Biology (FASEB), which lobbies for biomedical research funding. At the same time, massive pressure on overall federal spending will virtually freeze NIH's core funding.
On December 15, Congress passed a core NIH budget for 2012 of $30.7 billion, 1% more than it received in 2011. This is clearly better than the 1.5% decrease applied to most other federal spending. However, with $1.5 billion less in stimulus funds and inflation slowly eroding spending power, US biomedical research faces an unprecedented cut of more than 5%, in real terms, during 2012.
And 2013 is likely to be worse. After tortuous negotiations this October, a Congressional ''supercommittee'' failed to specify cuts in US government spending. This led Congress to implement a ''sequestration'' program that will automatically trim all government programs in 2013 and would cut NIH by another 8%-10%, according to FASEB.
It will be hard for either this Congress or the one elected in November to muster majorities to overturn the sequestration. Commentators believe that Democrats, in particular, may well block any changes to it, leaving NIH and other agencies to bite the bullet. ''Everyone says that across-the-board cuts are a crude way of doing things,'' asserts FASEB's legislative director, Jennifer Zeitzer. ''But there would be political fall-out from tampering with the sequestration plan.'' ''Whether Democrats or Republicans are in charge, they are going to have to get to grips with the deficit. Nobody sees science as exempt, but what the magnitude of the cuts will be [in future years] is anyone's guess,'' says Jim Siedow, a plant biologist and vice-provost for research at Duke University in North Carolina. Before the budget deal was struck, Siedow was planning for either a decrease or a very small increase in the 57% ''overhead'' payments that Duke receives on each NIH grant, which pay for its laboratories and services, such as libraries.
Stagnation Spreads across Europe
The general situation in the United States is being echoed all around the world as the recession bites. Biomedical research remains popular, both with the general public and with fiscal conservatives, who see it as a prudent investment. But after an initial rally to protect or even increase spending on it, the argument for sustaining biomedical research spending can get consumed by the general pressure to cut funding (see map).
In Canada, researchers were pleased that last year's budget brought CN $100 million (US $100 million 1 ) in extra funding for brain research, but they expect little good news in 2012. An austerity budget will be introduced in March, and finance minister Jim Flaherty has asked all agencies, including the Canadian Institute of Health Research and Health Canada, to plan for cuts of at least 5%. ''They still say science is important, but it isn't ring-fenced,'' says Paul Dufour, a longtime adviser on Canadian science programs based in Quebec.
In Britain, the UK Medical Research Council is better off than other agencies. ''We're not in a bad place,'' says its chief executive, John Savill. Though funds for all other fields of science in the UK have been frozen from 2011 to 2013, the MRC has been allocated small increases.
On December 5, Prime Minister David Cameron gave his first speech devoted to science. He laid out a life sciences strategy for the UK, which included various regulatory measures-and no new money for science. But Savill is not discouraged: ''The government is listening to the case we've made.''
The picture is mixed in mainland Europe. Germany powers ahead while the other major scientific nations retrench. The 2012 health research budget of BMBF, the German research and education ministry, will grow from E1.27 billion to E1.38 billion (US $1.8 billion), a rise of almost 9%. Even there, however, budgetary pressures are expected to slow the recent spurt in research spending by 2013.
France has announced a tiny increase of 0.4% in the 2012 budget of INSERM, the main biomedical research agency. But critics assert that the extra funding will be entirely consumed by the agency's growing pension commitment to its former staff. ''It's really a decrease, and more and more researchers are suffering because they don't get support,'' says Bertrand Monthubert, a mathematician at the University of Toulouse and former head of the grass roots scientists' group Sauvons La Recherche.
When economist Mario Monti took over as Prime Minister of Italy this past November, his first act was to pass a searing austerity budget, in outline. But the plan hasn't said yet where spending cuts will fall, researchers in the country say.
In Spain, researchers are cautiously optimistic that the new conservative government will try to protect science, says Enric Banda, director of the Catalan Research and Innovation Foundation in Barcelona.
Australia's economy has fared better than most developed countries in the recession. Under the current 3 year spending plan, funds for its National Health and Medical Research Council (NHMRC) will grow modestly from AU $850 million to AU $877 million (US $877 million) in the financial year that begins on April 1.
BRIC-Laying Continues
While most of these old imperial powers struggle to maintain their spending, emerging powers are doing much better. Brazil has a unique tradition of constitutionally tying research spending to a fixed percentage of the economy. This strategy has paid handsome dividends for researchers as their economy has boomed.
The strongest agency, FAPESP in Sao Paulo State, will increase its total budget next year by 12%, from BR $886 million to BR $993 million (US $540 million), according to its scientific director, Carlos Henrique de Brito Cruz. He also says that federal agencies are growing at a similar pace. Figures from the federal government suggest that total annual spending on health research in Brazil has doubled since 2005, to BR $1.5 billion (US $810 million) last year.
Biomedical research remains weak in Russia by any measure, but there have been promising developments lately, says Konstantin Severinov, a molecular biologist with posts at both the Russian Academy of Sciences (RAS) in Moscow and Rutgers University in New Jersey. For instance, a nanotechnology initiative of US $6 billion offered some support for life sciences; the Russian government introduced US $5 million ''megagrants'' to lure back é migré s; and some highquality programs, such the Molecular and Cell Biology program run by Georgii Georgiev, have evolved within RAS itself. Nonetheless, budgets next year will be flat at best, reckons Serverinov.
That certainly won't be the case in India. A new 5 year plan, which will be published in February and takes effect in April, is set to incorporate far bigger budgets for the two main health research agencies, the Department of Biotechnology (DBT) and the Indian Council of Medical Research (ICMR). The government in Delhi wants its own investments to catch up with the explosive growth of private sector pharmaceutical research by both Indian and foreign firms since patent reform in 2005. So DBT and ICMR are seriously pitching for increases of 40% each from their 2011 budgets of 14 billion (US $280 million) and 6 billion rupees (US $120 million), respectivelyalthough some observers think they'll settle for a 20% increase.
China appears to be equally dynamic, but its budget process is so opaque that OECD and other international bodies decline to estimate its R&D budgets. Nevertheless, the Institute of Policy and Management at the Chinese Academy of Sciences compiled an exhaustive survey of Chinese research compiled for UNESCO. It indicated that total Chinese public spending on health research was about 3 billion Yuan in 2008, which would have doubled to 6 billion Yuan (US $1 billion) last year. Observers believe that this spending will grow by about 20% again this year.
Other nations in East Asia continue to press ahead with expansion of their health research efforts. Programs in South Korea achieved spectacular growth rates for much of the last decade, but their expansion has slowed over the past 2 years. The 2012 budget has still to be set; it is expected to grow modestly.
Health research spending in Japan, which stood at about Y340 billion (US $4.4 billion) in 2011, has been stagnant for several years. But analysts say that it could increase by as much as 10% in 2012, as the government takes stimulus measures in response to last March's tragic earthquake at Fukashima.
The outlook has also improved somewhat in Singapore. Laboratory scientists are growing accustomed to new mechanisms that support research performed in collaboration with industry, according to George Radda, chair of its BioMedical Research Council. ''The worry that people had about how to access these funds is no longer there,'' he says. Total BMRC will grow only slowly, he adds, but at least it is assured for the next 4 years.
What Will the Repercussions Be?
All of these Eastern efforts should be seen, however, in the context of the huge slowdown in the dominant biomedical research power: the United States. Talking to researchers and officials around the globe, it is notable that expectations in North America have deteriorated sharply over the last year.
They are dire in Europe, too, but actual research spending there is holding up better than many feared, at least in the short term. And bold, medium-term expansion plans in Brazil, India, and the Far East must now be qualified by the fact that the overall economic slowdown is spreading into the developing world.
Overall, the picture last year was bleak, but it has darkened considerably since then. The word heard most frequently in interviews for this article was ''grim.'' By the start of 2013, it will become clearer if this is just a severe, cyclical setbackas most scientists, busying themselves in the lab, prefer to think-or if the great recession will shake the concept of large-scale, publicly funded biomedical research funding to its very core. 
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